3 days popular7 days popular1 month popular3 months popular

Protein biomarkers identified that predict time to ovarian cancer recurrence

often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated in prognosis. However, the genetic testing required is not practical or affordable in a clinical setting.

In this issue of the , Roel Verchaak and colleagues at the MD Anderson Cancer Center identify that are predictive for time of and develop a PRotein-driven index of OVARian cancer (PROVAR).

Using PROVAR, the authors were able to discriminate between patients with high and low risk of , as well as short-term and long-term survival prognosis. In combination with genetic diagnosis, analysis of protein biomarkers may be useful in predicting outcome and determining a treatment plan for .

TITLE: Predicting Time to Ovarian Carcinoma Recurrence Using Protein Markers

Source

J Clin Invest. doi:10.1172/JCI68509.

Journal of Clinical Investigation